Category Archives: Hormone Replacement Therapy

PITTSBURGH (TNS) Julie Bonnett has been a personal trainer and group fitness instructor for 22 years, amassing a list of certifications too numerous to name and a client list that includes some high-profile, and beloved, Pittsburgh athletes.

By happenstance, she trains mostly women, which is convenient, as she has 53 years of experience as a female herself and just as much experience supporting other women, as a friend, sister and daughter.

But none of that fieldwork prepared her for what confronts women as they approach midlife.

When people talked about perimenopause and menopause, no one really knew the answers. Theyd just turn to their friends, who also didnt have any answers, Bonnett said. Its been such a taboo topic. People didnt talk about it, and people in my age range, most people didnt talk to their moms about it.

As a trainer, she heard these concerns from her clients, not only because they sought the slimmer, more toned physiques of their younger years, but because they often werent getting satisfying answers from their medical practitioners.

These gaps in knowledge are an unfortunate equalizer, as research shows they exist for both women and those who care for them, on multiple continents and across demographic groups, with 80% of women under 40 reporting no knowledge at all or just some knowledge of the menopausal transition, as shown in a 2022 study.

But the tide is turning, and some University of Pittsburgh researchers are at the helm, proving that menopause is far more than hormones and hot flashes, but a profound physiological change in womens bodies worthy of focus, funding and a cultural shift toward acknowledging this stage of life differently.

Taming tabooPitt researcher Rebecca Thurston is a nationally recognized leader in womens health, particularly at the intersection of menopause, cardiovascular disease and brain health.

She, too, hears pleas from midlife women to feel understood.

Oftentimes, women are running around to different providers to figure this out, and then they run into some providers who are relatively uninformed about the perimenopause and menopause transition, she said. In that context, they can feel dismissed about what theyre experiencing due to, potentially, these information gaps between the scientific literature around menopause and it not quite making it out into clinical dissemination.

That educational lag may also speak to a well-documented history of womens concerns being dismissed in society at large, particularly around a topic such as this one, which highlights both ageism and sexism, Thurston noted.

But as new generations of women reach midlife, those conventions are changing.

You see Millennials and Gen Z, theyre like, forget it. Were not going to hide this very normal and natural life transition, she said. I also think there are more women who are in positions of power and authority across multiple different industries, and theres increasing impatience in having this transition be something thats cloaked in silence, shame and taboo.

Because of cultural and scientific stumbling blocks to fuller discussions about menopause, the change was often generalized to merely mean the end of menstrual periods and the vague idea that hormones are involved.

Its true that menopause occurs when a woman has been without a period for 12 consecutive months, and perimenopause is recognized as the body gears up for that change, which is orchestrated by hormonal changes. Also true: Women often suffer in silence as they experience a plethora of other symptoms, such as brain fog, the redistribution of fat, and changes in sleep and mood.

Science is catching up. Researchers are beginning to explain not only the signs and symptoms associated with perimenopause and menopause the differences that women can sense in their bodies or that others might notice but underlying physiologic changes, many of which were either unrecognized or previously thought to be age-related rather than unique to women in this stage.

Science as validation

After noticing how many of her clients and friends were trying to reinvent the same wheel in their 40s and 50s, Bonnett pursued a Menopause Coaching Specialist certification through Girls Gone Strong, an organization dedicated to women-focused certification programs and coaching, as informed by professionals from Yale, Johns Hopkins and Baylor universities and more.

The experience further proved how specialized this set of knowledge is.

For a long time, Ive known all of the things that can happen if you dont eat enough protein, but I learned, for instance, that it can contribute to the brain fog women deal with, she said.

She also learned these symptoms can be subtle, and start much earlier than many think, in womens late-30s.

While its validating to hear that others are experiencing similar symptoms, the emerging science might lead to the most significant forms of support, and maybe a hint of uncomfortable reality.

Samar El Khoudary, a Pitt epidemiologist and pharmacist, researches cardiovascular disease in midlife women, and how menopause may contribute.

Through her research, and some performed by others, the scientific community now knows that women experience an increase in LDL (the so-called bad cholesterol), total cholesterol and the main fatty-protein carried by LDL during this stage of life, contributing to atherosclerosis and cardiovascular disease.

Further, HDL cholesterol, or good cholesterol, may change as women progress through menopause, rendering it less cardio-protective than previously thought.

When I go to my PCP, they say, At least your HDL is high, El Khoudary said. But me, researching this, I know that doesnt necessarily mean Im protected.

Her teams research also showed that, within two years of the final menstrual period, women begin to accumulate fat in their abdomens, a more dangerous area due to the inflammatory markers and the higher risk of metabolic disease associated with it.

Its interesting because research shows that women gain weight with menopause, but the research also shows that gaining weight is an aging phenomena, she said. What is related to menopause is where we put the fat in our bodies.

That fat also deposits around the heart, shes discovered, where inflammatory markers, and increased cardiovascular risk, follows.

Further, its now understood that the carotid artery one of the bodys largest vessels, which brings fresh oxygen and nutrients to the brain increases in thickness and gets wider around menopause, making the artery less able to accommodate changes.

Thurstons research shows that women are having more hot flashes than they think as monitored by an innovative sweat gland-assessing device worn on the sternum and higher numbers of hot flashes are indicators of cardiovascular disease risk, while ones experienced overnight are indicators of poor brain health.

The last thing I want to do is scare women, but these hot flashes are telling us something, she said. The action item is to start being on top of your cardiovascular health, by knowing blood pressure and lipid numbers, monitoring insulin resistance, maintaining a heart-healthy diet and adhering to medical therapies.

Thurston sits on the advisory board for Astellas Pharma, the company that developed Veozah, an alternative to hormone replacement therapies for the treatment of hot flashes, approved by the FDA in May 2023.

And she completely agrees with newly published findings showing that hormone replacement therapy, for the relief of menopausal symptoms, isnt as dangerous as propounded in 2002, which stated that HRT was linked to an increased risk of blood clots, stroke and breast cancer.

As El Khoudary interacts with this body of research, she thinks of her mother.

When she was in this stage, we didnt know what she was dealing with, she said. She thought she was just having a hot flash, but never thought that could have implications for heart health.

El Khoudary believes research on the menopausal transition empowers women in ways not available to previous generations, even if some practitioners are still catching up.

When you go to your PCP, ask, I have heard this can happen to my lipids, can we check that? And thats really what the goal is, she said. Women should have informed discussions with their PCPs, so that conversations can lead to better checking, screening and making sure everything is going the way we want in that stage of their lives.

Menopause coaching specialists like Bonnett are available to reroute home-based lifestyle habits and refer to medical practitioners as needed. If those practitioners seem underprepared, Thurston recommends looking up The Menopause Society, a nonprofit that compiles a directory of menopause-trained providers.

But first, women are best served to listen to their bodies and their instincts.

Its not all in your head. If you think something is changing, it probably is, Thurston said. But while we tend to think about menopause and midlife aging as all doom and gloom, I will tell you that midlife can be a wonderful time for women.

Our job as providers is to help women harness the good, decrease the bad and sail through midlife, which can be a great time.

Read more:
When it comes to menopause, 'it's not all in your head,' and Pittsburgh-based research is proving it - Bradford Era

Hormone Replacement Therapy Market

Identify the impact of external forces impacting the industry growth especially in foreign markets, government, policies and regulations, consumer incomes and spending habits, new products entering in the market and their impact on the various industry players' products.

Get Quick Access to Sample Pages Now @ https://www.htfmarketintelligence.com/sample-report/global-hormone-replacement-therapy-market?utm_source=Krati_OpenPR&utm_id=Krati

According to HTF Market Intelligence, the Hormone Replacement Therapy Market is Anticipated to grow at a CAGR of 6.9% from 2023 to 2030

Hormone Replacement Therapy Market Overview Hormone Replacement Therapy (HRT) is a medical treatment involving the administration of hormones to supplement or replace hormones that the body no longer produces in adequate amounts. It is primarily used to alleviate symptoms caused by hormonal deficiencies or imbalances, such as those experienced during menopause or andropause (male menopause). HRT can involve the administration of estrogen, progesterone, testosterone, or a combination of these hormones, depending on the specific needs of the individual. The goal of HRT is to relieve symptoms and improve quality of life by restoring hormonal balance. However, it is important to note that HRT carries potential risks and benefits, and its use should be carefully considered and monitored under medical supervision.

Market Drivers: Increasing frequency of hormonal imbalances and related conditions and the increasing number of postmenopausal women and awareness of the benefits of HRT increasing is driving the market growth.

Market Opportunities: General practice and in Custom-made therapies are prescribed based on genetic information and individual hormonal needs to maximize efficacy and minimize side effects.

Highlighted of Hormone Replacement Therapy Market Segments and Sub-Segment:

Hormone Replacement Therapy Market by Key Players: Pfizer Inc. (United States), AbbVie Inc. (United States), Novo Nordisk A/S (Denmark), Bayer AG (Germany), Merck & Co., Inc. (United States), Eli Lilly and Company (United States), Mylan N.V. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Amgen Inc. (United States), Novartis AG (Switzerland)

Hormone Replacement Therapy Market by Types: Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Replacement, Others

Hormone Replacement Therapy Market by End-User/Application: Growth Hormone Deficiency, Hypothyroidism, Menopause, Others

Get Instant Discount (10-30% off) at Hormone Replacement Therapy Market Report https://www.htfmarketintelligence.com/request-discount/global-hormone-replacement-therapy-market?utm_source=Krati_OpenPR&utm_id=Krati

The study is a source of reliable data on Market segments and sub-segments, Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological innovations Value chain, and investor analysis.

Interpretative Tools in the Market: The report integrates the entirely examined and evaluated information of the prominent players and their position in the market by methods for various descriptive tools. The methodical tools including SWOT analysis, Porter's five forces analysis, and investment return examination were used while breaking down the development of the key players performing in the market.

Key Growths in the Market: This section of the report incorporates the essential enhancements of the marker that contains assertions, coordinated efforts, R&D, new item dispatch, joint ventures, and associations of leading participants working in the market.

Key Points in the Market: The key features of this Hormone Replacement Therapy market report include production, production rate, revenue, price, cost, market share, capacity, capacity utilization rate, import/export, supply/demand, and gross margin. Key market dynamics plus market segments and sub-segments are covered.

Basic Questions Answered *who are the key market players in the Hormone Replacement Therapy Market? *What are the regional growth trends and the leading revenue-generating regions for the Hormone Replacement Therapy Market? *What are the major Segments by Types for Hormone Replacement Therapy *What are the major applications of Hormone Replacement Therapy *Which Hormone Replacement Therapy technologies will top the market in the next decade?

Examine Detailed Index of full Research Study at@: https://www.htfmarketintelligence.com/report/global-hormone-replacement-therapy-market

Table of Content Chapter One: Industry Overview Chapter Two: Major Segmentation (Classification, Application, etc.) Analysis Chapter Three: Production Market Analysis Chapter Four: Sales Market Analysis Chapter Five: Consumption Market Analysis Chapter Six: Production, Sales, and Consumption Market Comparison Analysis Chapter Seven: Major Manufacturer's Production and Sales Market Comparison Analysis Chapter Eight: Competition Analysis by Players Chapter Nine: Marketing Channel Analysis Chapter Ten: New Project Investment Feasibility Analysis Chapter Eleven: Manufacturing Cost Analysis Chapter Twelve: Industrial Chain, Sourcing Strategy, and Downstream Buyers

Buy the Full Research Report of Hormone Replacement Therapy Market@: https://www.htfmarketintelligence.com/buy-now?format=1&report=9985?utm_source=Krati_OpenPR&utm_id=Krati

Thanks for reading this article; you can also get individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.

Nidhi Bhawsar (PR & Marketing Manager) HTF Market Intelligence Consulting Private Limited Phone: +15075562445 sales@htfmarketintelligence.com

About Author: HTF Market Intelligence Consulting is uniquely positioned to empower and inspire with research and consulting services to enable businesses with growth strategies, by offering services with extraordinary depth and breadth of thought leadership, research, tools, events, and experience that assist in decision-making.

This release was published on openPR.

Excerpt from:
Hormone Replacement Therapy Market: A Comprehensive Study Exploring with Bayer, Amgen, Novartis - openPR

Despite advances in our understanding of the risks and benefits of menopausal hormone therapy, outdated research continues to raise concerns for both patients and their clinicians.

Menopausal hormone therapy (MHT) has seen dramatic perception shifts over the past 70 years. From initially being lauded for cardiovascular protection, studies in the early 2000s caused widespread concern by highlighting both increased cardiovascular and breast cancer risks.

However, recent research reveals a more nuanced perspective and how there are many health and lifestyle benefits to MHT (also known as hormone replacement therapy or HRT), especially when started earlier.

A research article published in Research, Fertility and Development outlined the metamorphosis of MHT and explained how the risks and benefits are not fully understood or communicated.

The history of menopausal hormone therapy

According to author Professor Bronwyn Stuckey from the University of Western Australia, MHT used to be seen as largely beneficial for cardiovascular risk reduction.

When you talk to patients, wed say its better for bones, its better for cardiovascular, it reduces weight gain, and the only downside is [the risk of] breast cancer. And then wed talk about ways to mitigate that, she said.

However in 2002, the Womens Health Initiative (WHI) study was released, which reported both an increase in breast cancer and an increase in cardiovascular disease in women on MHT.

Initially, the statement was made that the increased risks for cardiovascular disease and invasive breast cancer were present across age strata. Results are likely to be generally applicable to healthy women in this age range. Professor Stuckey wrote in her article.

There was a huge media hype at the time and it caused a shift in attitudes of both doctors and patients away from MHT.

Even one of the co-authors of the WHI study mentioned that the treatment of menopausal symptoms has been derailed by the interpretation and editorial [of the WHI study], she told InSight+.

When the WHI study came out, the first author said that there was risk for cardiovascular disease across all age strata, which is not a correct statement. When you actually look at the WHI findings, the only group in which there was a significantly increased risk of cardiovascular events was the women who were more than 20 years past the menopause, and who had continuous combined HRT, Professor Stuckey explained.

In 2007, the WHI investigators published a more nuanced analysis of their data, which revealed the difference between the oestrogen-only and the oestrogen plus progestogen (E + P) MHT, and the difference between starting early after menopause and starting later, Professor Stuckey wrote.

There have also been several more studies analysing the risks and benefits of HRT, the timing of HRT and the types of therapies.

Current MHT therapies

According to the Royal Australian and New Zealand College of Obstetricians and Gynaecologists councillor, Dr Anna Clare, this recent research, including a 15 year follow-up to the WHI study, that showed neither cardiovascular mortality nor all-cause mortality were increased by MHT, is reassuring to clinicians and their patients.

I think from the point of view of starting hormonal therapy around the time of menopause, I think practitioners would feel pretty confident to reassure women that youre not at increased risk of cardiovascular disease, and actually risk is probably reduced by MHT, she said.

However, Professor Stuckey highlighted that much of this research hasnt been integrated into practice partly because the Monthly Index of Medical Specialties (MIMS) directions havent caught up with the evidence.

She told InSight+ that this evidence includes:

1) That there are no stopping rules for MHT. It can continue for as long as there is an indication.

2) Oestrogen is just as effective as an anti-resorptive agent to prevent fractures as drugs like bisphosphonate and denosumab, and much more appropriate for the young woman.

3) That the so-called window of opportunity does not mean that one cannot start MHT after 10 years past the last menstrual period. It just means the cardiovascular benefit may not be as great, but the benefit for vasomotor symptoms and quality of life will be just as great.

When informing patients about post-menopausal health, clinicians should compare the risk of breast cancer to the greater risk of cardiovascular disease and the effect of MHT on preserving bone density and decreasing the risk of type 2 diabetes. However, most importantly, is its impact on quality of life.

There are an increasing number of menopausal women in the workplace, increasing number of menopausal women in leadership roles. And there are more women internationally who are championing this, Michelle Obama, Davina McCall. Theyre saying menopause is a real thing, Dr Clare highlighted.

This resurgence of speaking about the problem combined with compelling research shows other women that they dont have to suffer in silence.

For many years, women have suffered menopause symptoms, which can be pretty debilitating and can really affect quality of life. And now more people are less worried about treating the symptoms with HRT because we have robust safety data, Dr Clare said.

When prescribing HRT, Professor Stuckey said although there are a few rules, a personalised approach is crucial.

There are a few overall rules, like no uterus = no progestogen because of the lower risk of breast cancer and the greater cardiovascular benefit with oestrogen-only MHT. However, transdermal oestrogen is preferred for people with risk of venous thrombosis or who have had a venous thrombosis, or for women with migraine which is sensitive to hormonal fluxes. Women who are very close to their last menstrual period will do better with cyclical MHT rather than continuous combined.

One of my colleagues once described choosing MHT formulae or preparations as a bit like trying on a dress to see which one suits you. One formulation will not suit everyone, she concluded.

Subscribe to the freeInSight+weekly newsletterhere. It is available to all readers, not just registered medical practitioners.

Excerpt from:
Mythbusting menopausal hormone therapy | InSight+ - MJA Insight

Penny Lancaster is opening up about going through the menopause.

While speaking to The Times in an interview published Thursday, June 20, Lancaster, 53, discussed some of her symptoms and revealed how her husband Rod Stewart helped her cope after she was originally misdiagnosed with depression.

The model and TV personality, who was 49 when she first started experiencing menopause symptoms, recalled how just before the COVID-19 pandemic started in March 2020, she suddenly, "Found that one night after another, I was waking up, sweating head to toe."

She and Stewart, 79 who tied the knot in 2007 after starting dating in 1999 were at their home in Florida at the time.

Mark R. Milan/GC Images

Lancaster, who thought she had COVID-19 at the time, explained, It wasnt just a little discomfort in the night. I was on top of the covers, feeling like this inferno was rising, as if I was standing in a pit of fire."

The heat started in my feet and rose up my legs. It was as if I could feel it going through my blood vessels, my blood was boiling. I could feel it rising, closer and closer to my heart and into my head," she went on.

"You think, How much hotter can I actually get? So Id wake up to the heat, to the fire bearing in mind we had air conditioning, it wasnt hot in the house find myself on top of the bedcovers, finally cooling down, and then, of course, waking up again, freezing cold because my temperature had settled, because my skin was damp and then cold with the air-con. Then back under the covers. And this was a vicious cycle for about four times a night, the policewoman added.

Ken McKay/ITV/Shutterstock

The PEOPLE Puzzler crossword is here! How quickly can you solve it? Play now!

At the time, Lancaster's fellow panelists on the U.K. talk show Loose Women suggested it might be menopause,but she thought she was too young.

At the end of March 2020, Lancaster, Stewart, and their two sons Alastair, 18, and Aiden, 13, returned to their U.K. home, which is when her symptoms got worse.

I had a few what I could classify as mental breakdowns, " she told the outlet, remembering how the family got chickens at the time and she became "the crazy chicken woman," hanging out in the animals' area.

One night at dinner, Lancaster revealed that father-of-eight Stewart and the two boys took a while to come down, and she ended up throwing the plates "across the kitchen."

Dave Benett/Getty

"I couldnt contain it anymore. I didnt want to hurt anyone. I didnt want to hurt myself. But I felt like it was getting to that point, she shared.

"I collapsed on the floor in a heap, burst into tears, shaking in the corner. Of course, it was an absolute shock to Rod and the boys. Rod just went, Boys, in the other room. Leave Mummy, " Lancaster said of her husband. "He came over and said, Its all right, darling. Its OK, its OK. I was shaking. I cant do this. What the hell is going on with me? I thought I was going mad. Rod said, Right, weve got to get you to the doctors. You cant carry on like this. Theres got to be an answer. Theres got to be something.

Lancaster said she was misdiagnosed with depression by one doctor, who gave her antidepressants The medication made Lancaster, who has no history of mental health issues, feel worse and just "numb," according to the outlet.

It was only when the Loose Women panelists performed an intervention and recommended Dr. Louise Newson a menopause specialist that she finally got some answers.

Never miss a story sign up forPEOPLE's free daily newsletterto stay up-to-date on the best of what PEOPLE has to offer, from juicy celebrity news to compelling human interest stories.

I burst into tears because of the good news," Lancaster told the outlet. Thats what it was. Im not going mad. I can save my marriage. I can keep my family together. I thought everything was falling apart.

Lancaster said Stewart "dealt with it very well.

Dr. Newson eventually weaned her off the antidepressants and prescribed hormone replacement therapy (HRT) instead, with Lancaster saying she felt better "almost immediately."

"Within a week or two, I slept through the night and my bedsheets werent wet. And then I could function during the day, and then I was just uplifted. I had more energy, more confidence," she said. "I wanted to start exercising again. The chicken hammock went into retirement. Thats not there any more. But that was a moment, definitely an important time to reflect on and to be able to talk about, like I am.

According to the Mayo Clinic, the menopause is the time that marks the end of your menstrual cycles. Symptoms include mood changes, hot flashes, mood changes, sleep problems, weight gain and thinning hair.

Read the original:
Rod Stewart Helped Wife Penny Lancaster with 'Inferno' of Menopause - PEOPLE

Lindora Recognizes Mens Health Month with Complimentary Testosterone Replacement Therapy (TRT) Exams and Labs

Leading Wellness Franchise Seeks to Raise Awareness for Hormone Imbalances and Benefits of TRT

The National Institute of Health estimates that 50% of men over the age of 80 are hypogonadal, meaning their bodies do not produce enough testosterone. Testosterone levels begin to decline in men starting around the age of 30, so Testosterone Replacement Therapy (TRT) can offer a viable solution to replenish this essential hormone. In recognition of Mens Health Month in June, Lindora, a leading provider of medically guided weight management programs and metabolic health solutions backed by Xponential Fitness, is raising awareness for the benefits of TRT and offering free TRT Initial Exam and Lab ($199 value) for male guests of members including family members, spouses, partners, or friends to book a consultation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240531308943/en/

In recognition of Mens Health Month in June, Lindora, a leading provider of medically guided weight management programs and metabolic health solutions backed by Xponential Fitness, is raising awareness for the benefits of TRT and offering free TRT Initial Exam and Lab ($199 value) for male guests of members including family members, spouses, partners, or friends to book a consultation. (Photo: Business Wire)

Hormone imbalances and deficits in men are not talked about enough, and Testosterone Replacement Therapy can be a safe and effective solution for so many to improve mood, metabolism, quality of life and more, said Dr. Amy Lee, Chief Medical Advisor for Lindora. We are excited to offer complimentary exams to referrals throughout June and see if TRT could be the best option for them, along with our other incredible health and wellness offerings.

TRT is a medical treatment used to restore a healthy testosterone level in men. It can involve replacing testosterone that the body is no longer producing adequately due to the natural aging process or other medical conditions. When prescribed and monitored appropriately by a medical professional at Lindora, TRT can significantly enhance a mans quality of life, metabolism, libido, ability to gain muscle mass, athletic performance and recovery, sleep quality, energy, mood, mental focus, and confidence. To know if a consultation and potentially TRT are right for a member, some of the symptoms of low testosterone include:

At Lindora, the initial TRT lab panel and comprehensive examination are performed by a Hormone Replacement Therapy (HRT) medical expert, beginning with a phone screen to discuss symptoms and medical history, and then once cleared for TRT, a comprehensive blood panel in person at a local Lindora. Members then undergo a medical consultation and exam with a Lindora HRT medical expert to discuss labs and determine the appropriate treatment plan and hormone treatment medications. Each quarter thereafter, the HRT medical expert will schedule a follow-up consultation and blood panel to monitor progress and adjust each members personalized treatment plan as needed. Memberships start at $229 per month, with a 2-month minimum, and include hormone treatment medications, follow-up consultations, body composition analysis, and quarterly blood panels.

While TRT can be safe and beneficial for many people, like any medical treatment, it has potential risks and side effects. Therefore, it is crucial to work with a healthcare provider and HRT experts like those at Lindora to address individual health risks and benefits.

Throughout Mens Health Month, Lindora is also encouraging all Wellness Members to share their membership benefits with an important man in their lives father, brother, son, spouse, partner, or close friend. Male referrals are welcome to enjoy product and service perks through June to discover how Lindora can help them achieve their holistic wellness goals, and if they join any Wellness Membership by June 30, theyll earn up to $150 in store credit.

For more information on Lindoras free TRT Initial Exam and Lab offer, please visit https://lp.lindora.com/trt. For more information about Lindora, please visit http://www.lindora.com.

ABOUT LINDORA:

Founded in 1971 in Southern California, Lindora is a leading provider of medically guided weight management programs and metabolic health solutions. Lindora guides people in creating sustainable lifestyle choices in nutrition, exercise and medicine through medically-guided weight management programs with personalized in-studio care. Lindora offers a suite of services that support metabolic health, including weight loss and management programs, weight loss medications including (GLP-1); hormone replacement therapy (HRT); and other services. Lindora is headquartered in Irvine, CA and backed by Xponential Fitness, a leading global franchisor of boutique health and wellness brands. To learn more about Lindora, visit https://www.lindora.com/.

David Robertson, Fishman Public Relations, drobertson@fishmanpr.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240531308943/en/

See the rest here:
Lindora Recognizes Men's Health Month with Complimentary Testosterone Replacement Therapy (TRT) Exams and ... - Morningstar

Report Ocean published the latest research report on the Hormone Replacement Therapy Market. In order to comprehend a market holistically, a variety of factors must be evaluated, including demographics, business cycles, and microeconomic requirements that pertain precisely to the market under study. In addition, the Hormone Replacement Therapy Market study demonstrates a detailed examination of the business state, which represents creative ways for company growth, financial factors such as production value, key regions, and growth rate. [Download Free Sample]

The global hormone replacement therapy market size was US$ 32.1 billion in 2021. The global hormone replacement therapy market is forecast to grow to US$ 51.1 billion by 2030 by growing at a compound annual growth rate CAGR of 6.1% during the forecast period from 2022 to 2030.

Request To Download Free Sample of This Strategic Report @-https://reportocean.com/industry-verticals/sample-request?report_id=Pol277

Hormonal replacement therapy (HRT) is a widely adopted method to cure problems or diseases related to the deficiency of a particular hormone. The hormone is available in various forms, such as transdermal, gels, injections, implants, tablets, and other forms.

The success of the global market is poised to drive innovative corporate objectives and competitive advantages. The report offers a panoramic view of the business environment, product specifications, and applications, offering valuable insights into the field. Furthermore, it scrutinizes the contributions of each region and market participant to the industry, shedding light on import/export statistics, consumer demand, manufacturing capacity, and pricing dynamics.

In a notable development, many prominent Hormone Replacement Therapy corporations appear to be inadvertently hastening their own decline by pursuing consolidation strategies aimed at enhancing profitability and reducing costs. The Hormone Replacement Therapy industry seems to have shifted its focus away from pioneering new concepts and products. Instead, it has embraced incremental innovation within its existing product portfolios, with most innovation efforts aimed at sustaining or marginally expanding current business operations. Furthermore, the industry is exploring alternative feedstock and power sources such as Biogas, hydrogen, and electric heating, potentially replacing natural gas.

Factors Influencing the Market

Hormone replacement therapy is widely suggested for people suffering from hypogonadism or other hormonal disorders. Thus, the growing prevalence of these disorders will fuel the growth of the global hormone replacement therapy market. In addition to that, the growing cases of menopause in women are likely to have a positive impact on the hormone replacement therapy market globally.

Growing concerns related to animals and plants will fuel the growth of the market. Hormones are injected into animals in order to decrease the gestation period. In addition, it also increases milk production and quality of meat, which will contribute to the growth of the global hormone replacement therapy market.

Ongoing R&D studies and the growing number of advancements in technology or healthcare will offer ample growth opportunities for the global hormone replacement therapy market.

The risk associated with the therapy, such as stroke, cancer, weight gain, or loss, may limit the market growth during the forecast period.

COVID-19 Impact Analysis

The wake of the COVID-9 pandemic marked potential growth for the global hormone replacement therapy market. Due to the pandemic, people became more aware of their health. In addition, a growing number of incidences related to hormonal imbalance surged the demand for efficient therapies. As a result, the global hormone replacement therapy market witnessed substantial growth. Moreover, estrogen is highly efficient in enhancing the immune response. Thus, all of these facts accelerated the growth of the market during the COVID-19 pandemic period.

Get a Free Sample PDF copy of the report @-https://reportocean.com/industry-verticals/sample-request?report_id=Pol277

Regional Analysis

North America is forecast to dominate the global hormone replacement therapy market. The growth of the market is attributed to the high healthcare expenditure and growing prevalence of diseases related to hormonal imbalance. In addition, high disposable incomes and a growing employment rate will significantly contribute to the growth of the market during the study period.

Competitors in the Market

As of the conclusion of 2022, the Hormone Replacement Therapy industry experienced growth in its workforce. In January, employment levels in the sector surpassed pre-COVID levels, with payrolls expanding by more than 15,000 people throughout 2022. The global Hormone Replacement Therapy output registered a 5.2% increase in 2021, driven by the global economic upswing and surging demand for commodities. However, in 2022, global industrial production declined following the 2021 boom, influenced by changes in consumer spending patterns and substantial fiscal stimulus measures.

The outlook for global Hormone Replacement Therapy output in 2023 indicates a projected growth rate of 2.9%. This growth is expected as production in Western Europe gradually regains momentum from its recent lows, and the Asia/Pacific regions production recovers. Notably, China maintains its position as the worlds largest producer and consumer of Hormone Replacement Therapy products, accounting for nearly 45% of the global market. Since 2010, Chinas market share has experienced consistent year-over-year growth, significantly contributing to the nations GDP. China also leads in exports of various products within the industry, including silicon, PVC, and specific Hormone Replacement Therapy market segments.

Market Segmentation

The global hormone replacement therapy market segmentation focuses on Therapies, Indication, Route administration, and Region.

Based on the therapies type, the hormone replacement therapy market has been segmented into

Download Sample Report, SPECIAL OFFER (Avail an Up-to 30% discount on this report ) @-https://reportocean.com/industry-verticals/sample-request?report_id=Pol277

Based on the indication, the hormone replacement therapy market has been segmented into

Based on the route administration, the hormone replacement therapy market has been segmented into-

Based on the region, the hormone replacement therapy market has been segmented into-

Get The Insights You Need By Customizing Your Report To Fit Your Unique Needs And Goals:-https://reportocean.com/industry-verticals/sample-request?report_id=Pol277

The report is structured as follows:

Chapter 1: Provides an overview of the global Hormone Replacement Therapy industry.

Chapter 3: Explores market dynamics.

Chapter 4: Profiles top industry companies.

Chapter 5: Analyzes global market competition among players.

Chapter 6: Examines the markets size across regions.

Chapter 7: Focuses on market segments by application.

Chapter 8: Dives into industry segments by type.

Chapter 9: Covers the market chain, sourcing strategies, and downstream buyers.

Chapter 10: Discusses strategies and key policies of distributors, suppliers, and traders.

Chapter 11: Analyzes key marketing strategies employed by market vendors.

Chapter 12: Examines factors affecting market dynamics.

Chapter 13: Forecasts the global Hormone Replacement Therapy market size for 2023-2031 and beyond.

The report aims to answer key questions in market research and analysis, such as:

What is the current market size, both in terms of value and volume?

What has been the historical growth rate, and what are the projected future growth rates?

Who are the major players, and what is their market share?

What are the prevailing market trends and dynamics?

What are the primary drivers of market growth?

What challenges and barriers do market participants face?

What emerging opportunities exist within the market?

How does the competitive landscape look?

What are consumer preferences, behaviors, and purchasing patterns?

How are different market segments performing?

What pricing trends and strategies are observed?

What are the distribution channels and their effectiveness?

Are there any regulatory and legal factors impacting the market?

The report provides a comprehensive and in-depth analysis of the global Hormone Replacement Therapy market, equipping stakeholders with valuable insights to make informed decisions in this dynamic industry.

Access Full Report Description, TOC, Table of Figure, Chart, etc.-https://reportocean.com/industry-verticals/sample-request?report_id=Pol277

About Report Ocean:

Report Ocean is a renowned provider of market research reports, offering high-quality insights to clients in various industries. Their goal is to assist clients in achieving their top line and bottom line objectives, thereby enhancing their market share in todays competitive environment. As a trusted source for innovative market research reports, Report Ocean serves as a comprehensive solution for individuals, organizations, and industries seeking valuable market intelligence.

Contact Information:

Email:[emailprotected]

Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, United States

Telephone: +1 888 212 3539 (US Toll-Free)

For more information and to explore their offerings, visit their website at:https://www.reportocean.com/

Read more:
Hormone Replacement Therapy Market is Dazzling Worldwide with Latest Rising Trends - Taiwan News

BUFFALO GROVE, Ill., June 2, 2024 /PRNewswire/ -- Tolmar Inc., a fully integrated pharmaceutical company, today announced results from a landmark survey of more than 300 US physicians, revealing barriers to treatment with testosterone-replacement therapy (TRT) among patients and physicians that, if addressed, may improve patient care.Detailed results of the survey will be presented at ENDO 2024, the signature annual meeting in endocrinology, in Boston on Sunday, June 2.The survey was conducted in partnership with the leading online physician community, Sermo.

"Men living with a testosterone deficiency have more treatment options than ever, but this expanded range of choices can be confusing. A key finding in the survey is that 66% of men on TRT switched therapy in the last year in order to find a form of therapy that works best for them. Not surprisingly, much of this is driven by insurance, but there is also a lack of awareness of newer and safe treatment options, like oral therapy, that may improve patient care," saidSandeep Dhindsa, M.B.B.S., Director of Division of Endocrinology, Diabetes and Metabolism, St. Louis University School of Medicine.

Uncovering Insights Into the Current TRT LandscapeResults from the survey showed challenges and potential solutions to effectively treat men with low or no testosterone. More than one-quarter of patients do not take their TRT as prescribed, according to physicians surveyed. For 71% of patients, oral medication is the preferred choice, but only 22% percent are aware of them. Lastly, half of physicians (50%) are unaware of current oral TRT and its proven safety profile.

"This reinforces the need for continued education on TRT and the importance of working closely with patients on a treatment plan. With a better understanding of safe and effective TRT options, we can improve adherence, minimize the need to switch treatments and help patients get the care they deserve," said AdrianDobs, M.D., Professor of Medicine and Oncology, The Johns Hopkins School of Medicine.

To explore the data driving these insights, visit http://www.JatenzoHCP.com to download the presentation of results and findings.

About the Survey In February 2024, Sermo conducted a survey of 303 physicians, including endocrinologists, urologists, primary care physicians and others experienced in prescribing testosterone-replacement therapy (TRT). The objectives of the survey were to: 1) understand the TRT patient experience and unmet needs; 2) outline prescribing behaviors and barriers across multiple specialties; and 3) uncover barriers to treatment and opportunities for patient and peer education.

About Tolmar Inc. Tolmar is a fully integrated pharmaceutical company focused on the development, manufacturing, and commercialization of specialty pharmaceuticals across multiple therapeutic areas, including Endocrinology. Tolmar's product development and manufacturing facilities are based in Northern Colorado and its executive offices and commercial headquarters are based in Buffalo Grove, Illinois. For more information about the company, please visit http://www.tolmar.com.

About Sermo Sermo is the largest global healthcare research company and the most trusted physician and provider engagement platform. Sermo engages with more than 1.5 million HCPs across 150 countries and has reach into the U.S. Payer market that now exceeds 230M commercial lives covered.For over 20 years, Sermo has been turning physician experience, expertise, and observations into actionable business insights that benefit pharmaceutical companies, healthcare partners, and the medical community at large. Sermo offers on-demand access to HCPs via a proprietary health-tech ecosystem to gain targeted HCP insights that inform strategic decisioning in real-time. To learn more, visit http://www.sermo.com.

About JATENZO

Indication

JATENZO (testosterone undecanoate) capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.

Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.

Limitation of use Safety and efficacy of JATENZO in males less than 18 years old have not been established.

IMPORTANT SAFETY INFORMATION

WARNING: INCREASES IN BLOOD PRESSURE

JATENZO can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death.

Before initiating JATENZO, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled.

Periodically monitor for and treat new-onset hypertension or exacerbations of pre-existing hypertension and re-evaluate whether the benefits of JATENZO outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease on treatment.

Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.

CONTRAINDICATIONS

JATENZO is contraindicated in men with breast cancer or known or suspected prostate cancer. JATENZO is contraindicated in women who are pregnant as testosterone may cause fetal harm.

WARNINGS AND PRECAUTIONS

Check hematocrit prior to initiation and every 3 months while a patient is on JATENZO and if hematocrit becomes elevated, stop JATENZO until hematocrit decreases to an acceptable level.

If hematocrit increases after JATENZO is restarted, stop permanently.

Monitor patients with benign prostatic hyperplasia (BPH) treated with androgens due to an increased risk for worsening signs and symptoms of BPH.

Venous thromboembolic events (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported in patients using testosterone replacement products like JATENZO. Evaluate patients with signs or symptoms consistent with DVT or PE and, if a VTE is suspected, discontinue JATENZO and initiate appropriate workup and management.

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids.

Large doses of androgens can suppress spermatogenesis by feedback inhibition of pituitary FSH. Inform patients of this risk before prescribing JATENZO. Prolonged use of high doses of methyltestosterone has been associated with serious hepatic adverse events. JATENZO is not known to cause these adverse events; however, patients should be instructed to report any signs of hepatic dysfunction and JATENZO should be discontinued while the cause is evaluated. Edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.

Gynecomastia may develop and persist in patients being treated for hypogonadism.

Sleep apnea may occur in some patients, especially those with risk factors such as obesity or chronic lung disease.

Changes in the serum lipid profile may require dose adjustment of lipid-lowering drugs or discontinuation of testosterone therapy. Monitor the lipid profile periodically, particularly after starting testosterone therapy.

Use JATENZO with caution in cancer patients at risk of hypercalcemia. Monitor serum calcium concentration regularly during treatment with JATENZO in these patients.

Androgens, including JATENZO, may decrease concentrations of thyroxine-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. Depression and suicidal ideation have been reported in patients treated with JATENZO in clinical trials.

ADVERSE EVENTS

The most common adverse events of JATENZO (incidence 2%) are headache (5%), increased hematocrit (5%), hypertension (4%), decreased HDL (3%), and nausea (2%).

These are not all of the risks associated with JATENZO. For more information, clickherefor full Prescribing Information, including BOXED WARNING on increases in blood pressure.

Company Contact: Steve Yuan [emailprotected] 224.880.1616

SOURCE Tolmar Inc.

Read the original post:
Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of ... - PR Newswire

Andrea Piacquadio via Pexels

By Stephen Beech via SWNS

Women who suffer hot flashes during menopause are more likely to develop a form of liver disease, warns new research.

Ice cream makers in America produce more than 1.38 billion gallons of ice cream annuallyenough for the typical American to eat roughly 20 pounds per year. Using Google Trends data for the 12-month period ending in April of 2024, researchers at Trace One, a company specializing in software f Click for more.The Most Popular Ice Cream Brand in Every State

Those experiencing moderate-to-severe flashes and night sweats - also known as vasomotor symptoms - face a three times greater risk of non-alcoholic fatty liver disease (NAFLD) compared to those with mild symptoms, according to the findings.

NAFLD affects up to one in four people worldwide. Most wont have symptoms, and some may never know they have the condition. But up to one-in-20 will experience complications from the fat in their livers.

Hot flashes and night sweats have become synonymous with menopause, say scientists.

Study lead author Dr. Eleni Armeni said: This research is significant as it contributes to understanding the link between vasomotor symptoms and cardiometabolic risk factors.

It is crucial for the general public because it emphasizes how hot flashes and night sweats can signal an increased risk for heart and metabolic issues.

The research team set out to analyze the likelihood of someone developing NAFLD related to menopause and the potential link with vasomotor symptoms.

Dr. Armeni, a research fellow at Kapodistrian University of Athens, Greece, said: Women experiencing these symptoms should consult a health care professional to address the symptoms and assess their cardiovascular health.

Photo by Andrea Piacquadio via Pexels

Previously, vasomotor symptoms were primarily seen as indicators of estrogen deficiency, but this study suggests broader implications for cardiovascular health related to this hormonal imbalance.

Dr. Armeni and her colleagues evaluated 106 peri- and post-menopausal women treated in an outpatient clinic.

The team estimated steatotic liver disease (SLD) to determine the risk on the fatty liver index. They took into account factors including age, exercise, alcohol, smoking, and hormone replacement therapy (HRT) use.

The results showed that 42 women with moderate-to-severe vasomotor symptoms had a three times higher risk for NAFLD compared with 64 women who had mild symptom severity.

That risk was 9.3 times higher when they limited the sample to those who experienced symptoms within five years after the menopausal transition.

Dr. Armeni added: We hope these findings will encourage healthcare providers to offer comprehensive care to peri- and post-menopausal women, going beyond discussions solely focused on hormone replacement therapy."

She is due to present the findings on Monday at ENDO 2024, the Endocrine Societys annual meeting in Boston, Mass.

Go here to read the rest:
Women with hot flashes during menopause at greater risk of this disease - News-Daily.com

State Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington D.C. West Virginia Wisconsin Wyoming Puerto Rico US Virgin Islands Armed Forces Americas Armed Forces Pacific Armed Forces Europe Northern Mariana Islands Marshall Islands American Samoa Federated States of Micronesia Guam Palau Alberta, Canada British Columbia, Canada Manitoba, Canada New Brunswick, Canada Newfoundland, Canada Nova Scotia, Canada Northwest Territories, Canada Nunavut, Canada Ontario, Canada Prince Edward Island, Canada Quebec, Canada Saskatchewan, Canada Yukon Territory, Canada

Zip Code

Country United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe

See the original post:
Global Hormone Replacement Therapy (HRT) Market Analysis 2024-2032 Featuring Abbott, Bayer, Eli Lilly & Co ... - Manchestertimes

Andrea Piacquadio via Pexels

By Stephen Beech via SWNS

Women who suffer hot flashes during menopause are more likely to develop a form of liver disease, warns new research.

Those experiencing moderate-to-severe flashes and night sweats - also known as vasomotor symptoms - face a three times greater risk of non-alcoholic fatty liver disease (NAFLD) compared to those with mild symptoms, according to the findings.

NAFLD affects up to one in four people worldwide. Most wont have symptoms, and some may never know they have the condition. But up to one-in-20 will experience complications from the fat in their livers.

Hot flashes and night sweats have become synonymous with menopause, say scientists.

Study lead author Dr. Eleni Armeni said: This research is significant as it contributes to understanding the link between vasomotor symptoms and cardiometabolic risk factors.

It is crucial for the general public because it emphasizes how hot flashes and night sweats can signal an increased risk for heart and metabolic issues.

The research team set out to analyze the likelihood of someone developing NAFLD related to menopause and the potential link with vasomotor symptoms.

Dr. Armeni, a research fellow at Kapodistrian University of Athens, Greece, said: Women experiencing these symptoms should consult a health care professional to address the symptoms and assess their cardiovascular health.

Photo by Andrea Piacquadio via Pexels

Previously, vasomotor symptoms were primarily seen as indicators of estrogen deficiency, but this study suggests broader implications for cardiovascular health related to this hormonal imbalance.

Dr. Armeni and her colleagues evaluated 106 peri- and post-menopausal women treated in an outpatient clinic.

The team estimated steatotic liver disease (SLD) to determine the risk on the fatty liver index. They took into account factors including age, exercise, alcohol, smoking, and hormone replacement therapy (HRT) use.

The results showed that 42 women with moderate-to-severe vasomotor symptoms had a three times higher risk for NAFLD compared with 64 women who had mild symptom severity.

That risk was 9.3 times higher when they limited the sample to those who experienced symptoms within five years after the menopausal transition.

Dr. Armeni added: We hope these findings will encourage healthcare providers to offer comprehensive care to peri- and post-menopausal women, going beyond discussions solely focused on hormone replacement therapy."

She is due to present the findings on Monday at ENDO 2024, the Endocrine Societys annual meeting in Boston, Mass.

Continue reading here:
Women with hot flashes during menopause at greater risk of this disease - Lebanon Democrat